NEVRO CORP (NVRO)
US64157F1030 - Common Stock
Overall NVRO gets a fundamental rating of 2 out of 10. We evaluated NVRO against 188 industry peers in the Health Care Equipment & Supplies industry. NVRO has a bad profitability rating. Also its financial health evaluation is rather negative. NVRO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
NVRO had negative earnings in the past year.
In the past year NVRO has reported a negative cash flow from operations.
NVRO had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NVRO reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -11.64%, NVRO is in line with its industry, outperforming 56.68% of the companies in the same industry.
NVRO's Return On Equity of -25.33% is in line compared to the rest of the industry. NVRO outperforms 57.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.64% | ||
| ROE | -25.33% | ||
| ROIC | N/A |
ROA(3y)-12.29%
ROA(5y)-13.9%
ROE(3y)-24.6%
ROE(5y)-28.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVRO's Gross Margin of 68.02% is fine compared to the rest of the industry. NVRO outperforms 77.01% of its industry peers.
NVRO's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for NVRO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
NVRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NVRO has been increased compared to 1 year ago.
The number of shares outstanding for NVRO has been increased compared to 5 years ago.
The debt/assets ratio for NVRO is higher compared to a year ago.
2.2 Solvency
NVRO has an Altman-Z score of -0.49. This is a bad value and indicates that NVRO is not financially healthy and even has some risk of bankruptcy.
NVRO has a Altman-Z score (-0.49) which is in line with its industry peers.
NVRO has a Debt/Equity ratio of 0.81. This is a neutral value indicating NVRO is somewhat dependend on debt financing.
NVRO's Debt to Equity ratio of 0.81 is on the low side compared to the rest of the industry. NVRO is outperformed by 75.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.49 |
ROIC/WACCN/A
WACC6.84%
2.3 Liquidity
A Current Ratio of 5.02 indicates that NVRO has no problem at all paying its short term obligations.
NVRO's Current ratio of 5.02 is fine compared to the rest of the industry. NVRO outperforms 73.26% of its industry peers.
NVRO has a Quick Ratio of 3.76. This indicates that NVRO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.76, NVRO is in the better half of the industry, outperforming 69.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.02 | ||
| Quick Ratio | 3.76 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.62% over the past year.
The Revenue has decreased by -0.86% in the past year.
NVRO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.88% yearly.
EPS 1Y (TTM)34.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.54%
Revenue 1Y (TTM)-0.86%
Revenue growth 3Y5.51%
Revenue growth 5Y1.88%
Sales Q2Q%-6.69%
3.2 Future
The Earnings Per Share is expected to grow by 12.69% on average over the next years. This is quite good.
The Revenue is expected to grow by 6.12% on average over the next years.
EPS Next Y-8.02%
EPS Next 2Y-1.13%
EPS Next 3Y6.31%
EPS Next 5Y12.69%
Revenue Next Year-4.51%
Revenue Next 2Y-1.07%
Revenue Next 3Y1.33%
Revenue Next 5Y6.12%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NVRO. In the last year negative earnings were reported.
Also next year NVRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.13%
EPS Next 3Y6.31%
5. Dividend
5.1 Amount
No dividends for NVRO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEVRO CORP
NYSE:NVRO (11/21/2024, 8:04:00 PM)
After market: 4.36 0 (0%)4.36
+0.13 (+3.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap162.54M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.64% | ||
| ROE | -25.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.02 | ||
| Quick Ratio | 3.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)34.62%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-8.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-0.86%
Revenue growth 3Y5.51%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y